// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis

R. Gadhok - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Efficacy of probiotics in inflammatory bowel disease: systematic review and meta-analysis

Y. Derwa - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Chromoendoscopy and narrow band imaging versus conventional white light endoscopy for detection of neoplasia in ulcerative colitis – a systematic review and meta-analysis

O. Har-Noy - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

The introduction of infliximab therapeutic drug level monitoring for is associated with cost savings in a cohort of patients in a large district general hospital

S. Whiteoak - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Infliximab

Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series

M. Zerncio - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD

C. Selinger - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Infliximab

Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?

K. Wade - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Allopurinol

A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel disease

Y. Derwa - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Therapeutic drug monitoring of anti-TNFα drugs in a UK tertiary IBD unit

V. Barrow - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis

P. Paschos - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Tasocitinib

Safety of anti-TNF treatment in liver transplant recipients – a meta-analysis

M. Westerouen van Meeteren - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections

F. Bhayat - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registry

E. Loftus, Jr - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Adalimumab

Evaluating the management of Vitamin D in Crohn's disease patients in a secondary care population

R. Ahmed - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Parathyroid hormone

Assessing internet based information used to aid patient decision making in surgery for perianal Crohn's fistula

J. Marshall - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis

M. Taylor - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Mesalamine

Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

J. Burisch - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

J. Burisch - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Epidemiology of genital lymphoedema as the initial presentation of paediatric Crohn's disease

F. Jagger - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Paediatric IBD patients do not meet the daily recommendations of vitamin D and calcium intake: survey based analysis in a tertiary centre

R. Shergill-Bonner - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Ergocalciferol

Copyright © 2026. QuantiNova All rights reserved